Recruitment unclearEUCTR 2018-001718-13
An Open- Label, Phase 2, Multicenter Feasibility Study if Manualized MDMA-Assisted Psychotherapy with an fMRI sub-study Assessing Changes in Brain Activity in Subjects with Posttraumatic Stress Dis...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesPTSD
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Czechia · Germany and 4 more locations
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Recruitment unclear
- Enrollment listed in the registry
- 40
- Sponsor
- MAPS Europe B.V.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom, Czechia, Germany, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2018-001718-13
- Official title
Show the full official title
An Open- Label, Phase 2, Multicenter Feasibility Study if Manualized MDMA-Assisted Psychotherapy with an fMRI sub-study Assessing Changes in Brain Activity in Subjects with Posttraumatic Stress Dis...
Recruitment & locations
Status unknownThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Czechia · Germany · Netherlands
3 more locations
- Norway
- Spain
- United Kingdom
Registry details
Historical country statuses
- Czechia — Completed
- Germany — Completed
- Spain — Prematurely Ended
- United Kingdom — GB - no longer in EU/EEA
- Netherlands — Completed
- Norway — Completed
Questions about this study
Who is behind this study?
The study sponsor is MAPS Europe B.V.
Want to explore more studies?
Explore studiesRelated studies
An open label study with objective sleepregistration on the effects of Doxazosin as treatment for PTSD, especially for sleep disturbance
Effects of ziprasidone vs. placebo during the first four weeks of eight weeks sertraline treatment in patients with PTSD (PTSD)